Free Trial
NASDAQ:XOMA

XOMA Royalty Q2 2024 Earnings Report

XOMA Royalty logo
$33.77 -0.43 (-1.26%)
Closing price 08/25/2025 04:00 PM Eastern
Extended Trading
$34.53 +0.76 (+2.25%)
As of 08/25/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Royalty EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.26
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$11.09 million
Expected Revenue
$8.37 million
Beat/Miss
Beat by +$2.72 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:45AM ET

Upcoming Earnings

XOMA Royalty's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Royalty Earnings Headlines

Analysts Set Expectations for XOMA Royalty FY2026 Earnings
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Royalty Profile

More Earnings Resources from MarketBeat